UroToday9d
ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy
The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...
UroToday7d
ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer
The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...
UroToday6d
Navigating Cancer Care Costs Videos
A Complex Landscape of Out-of-Pocket Expenses - Benjamin Pockros ...
UroToday2d
ASTRO 2024 Featuring Validation of Digital Pathology MMAI Algorithm and of the Decipher® Genomic Testing in the VANDAAM Study
Yang Song presented findings on the ArteraAI Prostate Test, a digital pathology multimodal artificial intelligence (MMAI) algorithm, which was shown to predict overall survival in patients with ...
UroToday4d
2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach
The Dutch Urological Association (NVU) has revised its guidelines for the treatment of urinary incontinence (UI) in secondary and tertiary care, updating the 2014 guidelines to address specific ...
UroToday4d
Does the Extent of Transurethral Resection after Radiation Therapy Impact Survival Outcomes in Muscle-Invasive Bladder Cancer - Expert Commentary
A current standard of care treatment for muscle-invasive bladder cancer (MIBC) is platinum-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Bladder-sparing protocols are ...
UroToday6d
When is prostate cancer really cancer?
Prostate cancer (PC) is a major cause of cancer-related deaths worldwide, with far more diagnoses than deaths annually. Recent discussions have challenged whether Grade Group 1 (GG1) PC should be ...
UroToday4d
Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases.
Metastases to the brain are rare in prostate cancer. Here, we describe a patient with two treatment-emergent metastatic lesions, one to the brain with neuroendocrine prostate cancer (NEPC) histology ...
UroToday4d
Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer
Background. The association between patient demographics and CV events after ADT using real-world data was evaluated. In addition to encompassing >30 times more patients than all previous MACE studies ...
UroToday4d
Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.
Immune checkpoint blockade (ICB) is currently the standard of care for metastatic renal cell carcinoma (RCC), but treatment responses remain unpredictable. Aristolochic acid (AA), a prevalent ...
UroToday5d
Clear cell renal cell carcinoma micrometastasis: Insights from an unconventional cutaneous presentation.
Clear cell renal cell carcinoma (ccRCC) is a highly lethal cancer known for its propensity to metastasise, yet the mechanisms underlying metastasis are not well defined. Cutaneous metastases from ...
UroToday4d
Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial.
Among cancer surgeries, patients requiring open radical cystectomy have the highest risk of red blood cell (RBC) transfusion. Prophylactic tranexamic acid (TXA) reduces blood loss during cardiac and ...